Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
gptkb:erythropoiesis-stimulating_agent gptkb:biosimilar |
| gptkbp:approvedBy |
gptkb:European_Union
|
| gptkbp:ATCCode |
B03XA01
|
| gptkbp:contraindication |
uncontrolled hypertension
hypersensitivity to epoetin zeta |
| gptkbp:developedBy |
gptkb:STADA_Arzneimittel
gptkb:Hospira |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
Retacrit
Silapo |
| gptkbp:mechanismOfAction |
stimulates erythropoiesis
|
| gptkbp:relatedTo |
gptkb:erythropoietin
|
| gptkbp:routeOfAdministration |
subcutaneous
intravenous |
| gptkbp:sideEffect |
hypertension
flu-like symptoms thromboembolic events |
| gptkbp:usedFor |
treatment of anemia
anemia in chronic kidney disease anemia in cancer patients undergoing chemotherapy |
| gptkbp:bfsParent |
gptkb:erythropoietin
|
| gptkbp:bfsLayer |
6
|
| https://www.w3.org/2000/01/rdf-schema#label |
epoetin zeta
|